Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study

EuroMRD; EuroClonality-NGS Working Group

doi:10.1038/s41375-021-01154-z

Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study

EuroMRD, EuroClonality-NGS Working Group

Research related

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

6 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	924-928
Aantal pagina's	5
Tijdschrift	Leukemia
Volume	35
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1038/s41375-021-01154-z
Status	Gepubliceerd - mrt. 2021

Toegang tot document

10.1038/s41375-021-01154-z

Citeer dit

@article{55f01e67643749dda6fa33a150b5ef09,

title = "Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study",

author = "EuroMRD and {EuroClonality-NGS Working Group} and {van der Velden}, {Vincent H.J.} and Monika Br{\"u}ggemann and Giovanni Cazzaniga and Blanca Scheijen and Bastiaan Tops and Jan Trka and Karol Pal and Sonja H{\"a}nzelmann and Grazia Fazio and Simona Songia and Langerak, {Anton W.} and Nikos Darzentas and {van der Velden}, {Vincent H.J.}",

note = "Funding Information: Acknowledgements GC was supported by a grant from the Italian Association for Cancer Research (AIRC), grant IG2015-17593. BS was supported by a grant from the Dutch Cancer Society (2017/ 11137). Funding Information: Conflict of interest The EuroClonality-NGS Working Group is an independent scientific subdivision of EuroClonality that aims at innovation, standardization and education in the field of diagnostic clonality analysis. The revenues of the previously obtained patent (PCT/NL2003/000690), which is collectively owned by the Euro-Clonality Foundation and licensed to InVivoScribe, are exclusively used for EuroClonality activities, such as for covering costs of the Working Group meetings, collective WorkPackages and the Euro-Clonality Educational Workshops. The EuroClonality consortium operates under an umbrella of ESLHO, which is an official EHA Scientific Working Group. VHJvdV: contract research for Pfizer and Janssen, Service Level Agreements with BD Biosciences and Agilent. MB reports personal fees from Incyte (advisory board), financial support for reference diagnostics from Affimed, Amgen and Regen-eron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), personal fees from Janssen (speakers bureau), personal fees from Molecular Health (advisory board), all outside the submitted work. AWL: contract research for Roche-Genentech, research support from Gilead, advisory board for AbbVie, speaker for Gilead, Janssen. The other authors declare no conflict of interest.",

year = "2021",

month = mar,

doi = "10.1038/s41375-021-01154-z",

language = "English",

volume = "35",

pages = "924--928",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study

AU - EuroMRD

AU - EuroClonality-NGS Working Group

AU - van der Velden, Vincent H.J.

AU - Brüggemann, Monika

AU - Cazzaniga, Giovanni

AU - Scheijen, Blanca

AU - Tops, Bastiaan

AU - Trka, Jan

AU - Pal, Karol

AU - Hänzelmann, Sonja

AU - Fazio, Grazia

AU - Songia, Simona

AU - Langerak, Anton W.

AU - Darzentas, Nikos

AU - van der Velden, Vincent H.J.

N1 - Funding Information: Acknowledgements GC was supported by a grant from the Italian Association for Cancer Research (AIRC), grant IG2015-17593. BS was supported by a grant from the Dutch Cancer Society (2017/ 11137). Funding Information: Conflict of interest The EuroClonality-NGS Working Group is an independent scientific subdivision of EuroClonality that aims at innovation, standardization and education in the field of diagnostic clonality analysis. The revenues of the previously obtained patent (PCT/NL2003/000690), which is collectively owned by the Euro-Clonality Foundation and licensed to InVivoScribe, are exclusively used for EuroClonality activities, such as for covering costs of the Working Group meetings, collective WorkPackages and the Euro-Clonality Educational Workshops. The EuroClonality consortium operates under an umbrella of ESLHO, which is an official EHA Scientific Working Group. VHJvdV: contract research for Pfizer and Janssen, Service Level Agreements with BD Biosciences and Agilent. MB reports personal fees from Incyte (advisory board), financial support for reference diagnostics from Affimed, Amgen and Regen-eron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), personal fees from Janssen (speakers bureau), personal fees from Molecular Health (advisory board), all outside the submitted work. AWL: contract research for Roche-Genentech, research support from Gilead, advisory board for AbbVie, speaker for Gilead, Janssen. The other authors declare no conflict of interest.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85102608202&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01154-z

DO - 10.1038/s41375-021-01154-z

M3 - Letter

C2 - 33608635

AN - SCOPUS:85102608202

SN - 0887-6924

VL - 35

SP - 924

EP - 928

JO - Leukemia

JF - Leukemia

IS - 3

ER -